Is the Routine Use of Drugs Containing Glutamine or Krebs’ Cycle Intermediates Safe in Apparent or Hidden Cancer Pathology?

L.O. Maltseva, N.F. Mosentsev, O.V. Mosentseva, L.V. Kunyk, D.V. Bazylenko


It was analyzed the published data regarding the bioenergetic, biosynthetic and metabolic spectrum of action of glutamine on tumor cells. Much attention is paid to the increased consumption of glutamine by tumor cells, which is one of the molecular basis of tumorgenesis. Blocking anaplerotic enter of glutamine into the citric acid cycle increases the sensitivity of tumor cells to cytostatic drugs.


tumor cells; glutamine; citric acid cycle


Wang J.B., Erickson J.W., Fuji R., Ramachandran S. et al. Targeting Mitochondrial Glutaminase Activity Inhibits Oncogenic Transformation // Cancer Cell. — 2010. — ​Vol. 18, iss. 3. — ​P. 207-219.

Wise D.R., Thompson C.B. Glutamine Addiction: A New Therapeutic Target in Cancer // Trends Biochem. Sci. — 2010. — ​Vol. 35. — ​P. 427-433.

Semenza G.L. Regulation of Metabolism be hypoxia-inducible Factor 1 // Quant. Biol. — 2011. — ​Vol. 76. — ​P. 347-353.

Tannahill G.M., Curtis A.M., Adamik J., Palsson-McDermott E.M. et al. Succinate is an inflammatory signal that induces IL‑1β through HIF‑1α // Nature. — 2013. — ​Vol. 496. — ​P. 238-242.

Semenza G.L. HIF‑1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations // The Journal of Clinical Investigation. — 2013. — ​Vol. 123, № 9. — ​P. 3664-3671.

Sciacovelli M., Guzzo G., Morello V., Frezza C. et al. The mitochondrial chaperone TRAP1 promotes neoplastic growth by inhibiting succinate dehydrogenase // Cell Metabolism. — 2013. — ​Vol. 17, iss. 6. — ​P. 988-999.

Copyright (c) 2016 EMERGENCY MEDICINE

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2018


   Seo анализ сайта